This is a preprint.
Strain heterogeneity in a non-pathogenic fungus highlights factors contributing to virulence
- PMID: 38496489
- PMCID: PMC10942418
- DOI: 10.1101/2024.03.08.583994
Strain heterogeneity in a non-pathogenic fungus highlights factors contributing to virulence
Update in
-
Strain heterogeneity in a non-pathogenic Aspergillus fungus highlights factors associated with virulence.Commun Biol. 2024 Sep 4;7(1):1082. doi: 10.1038/s42003-024-06756-8. Commun Biol. 2024. PMID: 39232082 Free PMC article.
Abstract
Fungal pathogens exhibit extensive strain heterogeneity, including variation in virulence. Whether closely related non-pathogenic species also exhibit strain heterogeneity remains unknown. Here, we comprehensively characterized the pathogenic potentials (i.e., the ability to cause morbidity and mortality) of 16 diverse strains of Aspergillus fischeri, a non-pathogenic close relative of the major pathogen Aspergillus fumigatus. In vitro immune response assays and in vivo virulence assays using a mouse model of pulmonary aspergillosis showed that A. fischeri strains varied widely in their pathogenic potential. Furthermore, pangenome analyses suggest that A. fischeri genomic and phenotypic diversity is even greater. Genomic, transcriptomic, and metabolomic profiling identified several pathways and secondary metabolites associated with variation in virulence. Notably, strain virulence was associated with the simultaneous presence of the secondary metabolites hexadehydroastechrome and gliotoxin. We submit that examining the pathogenic potentials of non-pathogenic close relatives is key for understanding the origins of fungal pathogenicity.
Keywords: comparative genomics; evolution of virulence; fungal pathogenicity; gliotoxin; secondary metabolism; specialized metabolism; virulence factor.
Conflict of interest statement
CONFLICT OF INTEREST A. R. is a scientific consultant for LifeMine Therapeutics, Inc.
Figures
References
-
- Drgona L., Khachatryan A., Stephens J., Charbonneau C., Kantecki M., Haider S. & Barnes R. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 33, 7–21 (2014). - PMC - PubMed
-
- Vallabhaneni S., Mody R. K., Walker T. & Chiller T. The Global Burden of Fungal Diseases. Infect. Dis. Clin. North Am. 30, 1–11 (2016). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources